Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases

Kirk Sperber*1, Christine Hom2, Chun Peng Chao2, Deborah Shapiro1 and Julia Ash1

Address: 1Division of Allergy, Immunology, and Rheumatology, Department of Medicine, New York Medical College, Munger Pavilion, Valhalla, NY 10595, USA and 2Division of Rheumatology, Department of Pediatrics, New York Medical College, Munger Pavilion, Valhalla, NY 10595, USA

Email: Kirk Sperber* - kirk_sperber@NYMC.edu; Christine Hom - Christine_hom@NYMC.edu; Chun Peng Chao - Chun_PengChao@NYMC.edu; Deborah Shapiro - Deborah_Shapiro@NYMC.edu; Julia Ash - Julia_Ash@NYMC.edu

* Corresponding author

Abstract

Objective: The purpose of this study is to compare the incidence of congenital defects, spontaneous abortions, number of live births, fetal death and pre-maturity in women with autoimmune diseases taking HCQ during pregnancy.

Methods: The authors searched MEDLINE, Cochrane data base, Ovid-Currents Clinical Medicine, Ovid-Embase:Drugs and Pharmacology, EBSCO, Web of Science, and SCOPUS using the search terms HCQ and/or pregnancy. We attempted to identify all clinical trials from 1980 to 2007 regardless of language or publication status. We also searched Cochrane Central Library and http://www.Clinical trials.gov for clinical trials of HCQ and pregnancy. Data were extracted onto standardized forms and were confirmed.

Results: The odds ratio (OR) of congenital defects in live births of women taking HCQ during pregnancy was 0.66, 95% confidence intervals (CI) 0.25, 1.75. The OR of a live birth for women taking HCQ during pregnancy was 1.05 (95% CI 0.58, 1.93). The OR of spontaneous abortion in women taking HCQ during pregnancy was 0.92 (95% CI 0.49, 1.72). The OR of fetal deaths in women taking HCQ during pregnancy was 0.97 (95% CI 0.14, 6.54). The OR of pre-mature birth defined as birth before 37 weeks in women taking HCQ during pregnancy was 1.10 (95% CI 0.75, 1.61).

Conclusion: HCQ is not associated with any increased risk of congenital defects, spontaneous abortions, fetal death, pre-maturity and decreased numbers of live births in patients with auto-immune diseases.

Background

The anti-malarial drugs Hydroxychloroquine (HCQ) is widely used to treat various rheumatic diseases [1]. The mechanism of action of this drug is to increase the pH in acidic vesicles, inhibiting receptor mediated endocytosis that affects many cellular functions including antigen presentation, toll receptor signaling and post-transcriptional modification of proteins [2-4]. Convincing evidence has accumulated over the past years demonstrating the efficacy of HCQ in the treatment of auto-immune dis-
eases including systemic lupus erythematosus (SLE), dis-
coid lupus erythematosus (DLE) and rheumatoid arthritis
(RA) [5,6]. Since many rheumatic diseases affect women
of child bearing age, there have been concerns regarding
potential teratogenic and toxic effects of the drug on the
developing fetus [7,8].

Malformations and other abnormalities after treatment
with higher than the recommended dose of (Chloro-
quine) CQ through pregnancy were reported after intrau-
terine exposure to 500 mg daily of CQ in 3 siblings [9]. In
animal model systems the drug accumulates in the pig-
mented cells in the eye [10,11]. Dose-dependent retinal
toxicity has long been recognized as the major side effect
of HCQ [10,11]. CQ crosses the placenta during preg-
nancy [12]. In an evidence-based guideline evaluating the
risks and benefits of drug therapies during pregnancy, it
was recommended to continue HCQ during pregnancy
and lactation [13]. Although there have been a number of
reviews regarding the use of HCQ during pregnancy [14-
16], to date there has been no meta-analysis analyzing the
effect of HCQ on fetal outcomes in women with various
auto-immune diseases. This systematic review contains a
meta-analysis of the available clinical studies investigating
the use of HCQ during pregnancy and will focus on the
risk of congenital defects, number of live births, spontane-
ous abortions, fetal deaths and pre-maturity in fetuses
born to women taking HCQ.

Materials and methods
Study Selection
We searched the Cochrane data base, Ovid-Current Con-
tents-Clinical Medicine, Ovid-Embase-Drugs and Phar-
macology, EBSCO, Medline, Web of Science, and
SCOPUS using the search terms HCQ and/or pregnancy.
We attempted to identify all clinical trials from 1980 to
2007 regardless of language or publication status. We also
searched Cochrane Library and http://www.Clinical_tri-
als.gov for clinical trials of HCQ and/or pregnancy. We also
checked the citations of literature reviews and of all trials
identified in our search. Potentially relevant studies
describing HCQ during pregnancy were retrieved and
examined. Figure 1 is a diagram of the process that was
used to select the studies included in the meta-analysis.
Comparative studies of any design were considered but
those studies without a non-HCQ group were excluded.
Studies were eligible for inclusion if the investigators had
pregnant patients in a non-HCQ treatment group and
reported clinical outcomes in the fetus.

Data Extraction and Quality Assessment
We used previously published methods to determine the
quality of the observational studies used in systematic
reviews [17,18]. The control groups in the included stud-
ies were similar to the HCQ groups for sex, age, criteria for
SLE, DLE, RA or other autoimmune diseases as estab-
lished by American College of Rheumatology (ACR). Two
of the authors extracted all of the data onto a standardized
form that was confirmed by the corresponding author.
The primary outcomes considered in this review were con-
genital defects, spontaneous abortions, fetal deaths, pre-
maturity (birth before 37 weeks of gestation) and live
births. Two raters reviewed and scored the articles inde-
dependently by using a checklist designed by Downs and
Black [19]. In cases of divergence of the results between
the two raters, a third rater reviewed the articles and rated
the quality scores again to choose the most plausible
results. The checklist designed by Downs and Black was
developed for the purpose of quality assessment of both
randomized and nonrandomized studies with health
interventions and consists of five subscales: reporting,
internal validity bias, internal validity confounding, exter-
nal validity, and power [19]. Because six items in the orig-
inal list were related to randomization, and power
calculation, their scores were counted as zero. The maxi-
mum score on the quality scales is 31 points; these were
summed and a higher score is considered to be an indica-	or of a better quality study. For observational studies, a
quality score of 12 or greater is considered excellent
[19,20].
Data Synthesis and Analysis
Data for congenital defects, spontaneous abortions, fetal deaths, pre-maturity (Birth before 37 weeks of gestation) and live births were pooled and analyzed by using the Cochrane Collaboration Review Manager software (Nordic Cochrane Centre, Copenhagen, Denmark) [20]. We used Review Manager 4.2 for the analysis. A fixed effect model of the inverse variance method was used when the effects were assumed to be homogenous. The random effect model of the DerSimonian and Laird approach was used when they were assumed to be heterogeneous [21]. To test the publication bias, funnel plots were drawn with the treatment effect measure on the horizontal axis and the study size on the vertical axis, and Harbord test was performed [22,23]. We used odds ratios (OR) for dichotomous variables in this study. Heterogeneity between studies was assessed by using chi-square and I² tests, a p value of less than 0.1 and an I² value of 50% were considered high [24].

We calculated the number of subjects that would have to be included in the meta-analysis for each of the variables, congenital defects, spontaneous abortions, fetal deaths, pre-maturity and live births, to have a power of 0.80 and a one sided p value of 0.05 in pregnant patients taking HCQ [25]. The likelihood that we would be able to detect an association between HCQ and congenital defects, live births, spontaneous abortions, fetal deaths, and pre-maturity is dependent on the magnitude of that association. We can determine an effect size of 0.20 for congenital defects, live births, spontaneous abortions, fetal deaths, and pre-maturity given the number of pregnancies that are included in this analysis (290 pregnancies on HCQ, 341 pregnancy controls) [26].

Data from randomized placebo-controlled trials (RCTs) should not be combined with observational studies in a meta-analysis [17,18]. Since one of the observational studies was a case controlled study, we used odds ratios (OR) for the study variables [24].

Role of Funding Source
This study was not funded by any outside agency or pharmaceutical company.

Results
The literature search for HCQ and/or pregnancy identified 82 abstracts. After review of the abstracts and exclusion of non-trials and trials that did not compare pregnant women with auto-immune diseases taking HCQ with a control group, we identified 5 studies of interest [27-31] (Figure 1). The studies were published within the past 15 years. Searches of the Cochrane Library and of the http://www.Clinical Trials.gov website did not return any entries of HCQ and pregnancy. This was a safety study which presents considerable difficulties in obtaining sufficient numbers of patients to include in the meta-analysis. Since there are more observational studies than experimental studies in determining the safety of HCQ in pregnancy we included studies of any design for the meta-analysis. [32]. Seventy-seven articles were excluded including 68 with no non-HCQ control group and 3 with no outcomes of interest (Figure 1).

Quality assessment of the articles
Four of the 5 studies were observational [27-30] and one was a randomized placebo controlled double-blinded trial [31]. Three of the 4 observational studies were published as full manuscripts [27-30] and one was presented as an abstract [30]. One of the observational studies was a case controlled study [30] while the other 3 were cohort studies [27-29]. The first observational study had 69 Lupus patients, 13 unclassified connective tissue disease and 8 patients with primary Sjogren’s syndrome [28], the second observational study included 197 women all diagnosed with Lupus [27], the third observational study also followed 86 Lupus patients [29], as well as the fourth observational study 142 women with connective tissue diseases [30] (Additional file 1, Table S1). Only one study was conducted in the United States [27].

The quality of the studies we identified based on the Downs and Black checklist ranged from 20 to 25. Although the double-blinded placebo controlled trial was of the highest quality we did not include it in our analysis [31] for statistical reasons as noted previously [17,18]. We used the Harbord test to investigate funnel plot asymmetry in the analysis because we measured dichotomous variables [23]. This test avoids the mathematical association between log odds ratio and its standard error proposed by Egger et al [18] when there is a substantial intervention effect, while retaining power compared with alternative tests. However, false-positives may occur in the presence of substantial between-study heterogeneity. We did not observe any substantial heterogeneity in the studies in the meta-analysis and no publication bias.

OR of congenital defects and live births
Other studies have reported that HCQ is safe to use during pregnancy but had no control group [35-40]. All 4 of the studies [27-30] assessed the presence of congenital defects in babies born to women with autoimmune diseases (Additional file 1, Table S2 and Figure 2a). The OR for congenital defects for the pooled data for patients taking HCQ during pregnancy compared to no drug was 0.66 (95% CI, 0.25, 1.75) which favored HCQ (Additional file 1, Table S2 and Figure 2a).

Consonant with the results obtained for the OR of congenital defects, all 4 of the included studies did not report
Figure 2
OR of congenital defects and live births. The OR for congenital defects (2A) and live births (2B) from the pooled data in the HCQ group compared to the control group was determined.
any differences in the OR of live births comparing women who took HCQ compared to the control group (Additional file 1, Table S2 and Figure 2b.) The OR for live births of the pooled data in the HCQ group compared to the control group was 1.10 (95% CI, 0.61, 1.99) (Figure 2b).

**OR of spontaneous abortion and fetal death**

Women with SLE have a higher incidence of spontaneous abortions and fetal loss [41,42]. Some investigations have shown a correlation between disease activity, spontaneous abortion, and fetal loss in pregnant SLE patients. Different authors have reported a variety of frequencies of spontaneous abortions and fetal loss with rates varying between 11% and 24% [43-47]. Data were available from the 4 studies [27-30] that defined spontaneous abortion and fetal death defined as death occurring after 20 weeks of gestation. The pooled estimate of the OR of spontaneous abortion for the patients taking HCQ compared to placebo was 0.92 (95% CI 0.49, 1.72) which favored the HCQ group (Additional file 1, Table S2 and Figure 3a).

In line with the results for spontaneous abortions, all 4 studies reported the OR of fetal death [25-28] (Additional file 1, Table S2 and Figure 3b). The pooled OR for fetal death was 0.94 (95% CI 0.14, 6.54) which again favored the patients taking HCQ. There is variability in the fetal death rate probably due to the small sample size.

**OR of prematurity**

Higher incidences of premature births have been described in SLE patients especially in patients who have active disease [44,45]. Consistent with the results for congenital defects, live births, spontaneous abortions, and fetal deaths, there was no increased risk of pre-maturity associated with HCQ treatment. Data are available from the 4 studies regarding pre-mature death (Additional file 1, Table S2 and Figure 4). The pooled OR was 1.08, (95% CI, 0.74, 1.57).

**Discussion**

Our systematic review provides evidence for the use of HCQ during pregnancy for women with auto-immune diseases. We identified 3 cohort studies [27-29] and 1 case-controlled study [30] comparing HCQ treatment with no HCQ treatment in pregnant women with autoimmune diseases (Figure 1 and Additional file 1, Tables S1 and S2). We attempted to identify all relevant studies regarding HCQ and pregnancy by not restricting our literature search to the English language. It is still possible that we may have inadvertently omitted other studies that were not identified in the literature searches of the different databases.

Although the Harbord test for dichotomous variables did not indicate publication bias, citation bias, and database bias, the number of studies included in our meta-analysis was only 4 so that it is possible that it may not be able to distinguish chance from real asymmetry in the funnel plot. The quality of the studies that were included in this meta-analysis as determined by the Downs and Black checklist was excellent despite the fact that they were no randomized placebo-controlled clinical trials [19,20]. The scores are listed in Additional file 1, Table S1.

We did not observe any heterogeneity in the results of the different studies (Figures 2a, b, 3a, and 4) that could have arisen because of differences in doses of HCQ (200 mg compared to 400 mg), length of follow up after birth, and between auto-immune diseases (SLE, DLE, RA, Sjogren’s syndrome), allowing the use of a fixed effect model for. The only significant heterogeneous result between the studies was the increased risk of fetal deaths (Figure 3b) noted where the results were analyzed by using a random-effects model.

Our study was limited by the lack placebo controlled double-blinded studies that compared HCQ therapy with a control group. The patient populations included in the studies were fairly homogenous. All of the studies included pregnant females of child bearing age with autoimmune disease predominantly Lupus who met the ACR criteria for diagnosis, all of the patients and the fetuses were exposed to HCQ at the time of conception and throughout the pregnancy, all of the studies had a control group who were not exposed to the drug, and all reported similar outcomes.

We did not include the 1 RCT [31] because of the difficulties of combining different study designs in meta-analysis as noted above [17,18]. This study also found no differences in congenital defects, number of live births, fetal death, and pre-maturity in patients who were treated with HCQ compared to those who were not treated with HCQ. Despite the fact that we performed a meta-analysis, our studies were underpowered to detect an association between congenital defects congenital defects, spontaneous abortions, fetal deaths, pre-maturity and live births, if the effect of HCQ is less than 0.2 [48]. We did consider adding isolated case reports in our analysis given the rarity of the occurrence of congenital malformations and other obstetrical complication of this drug [35-40]. However, we did not include these patients in the statistical analysis because there were no control groups.

There have been numerous studies using CQ prophylaxis for malaria during pregnancy. CQ, a pharmacologic analogue of HCQ has been used in Europe to treat auto-immune diseases and its mechanism of action is identical.
Figure 3
**OR of spontaneous abortion and fetal death.** The pooled estimate of the OR of spontaneous abortion (3A) and fetal death (3B) for the patients taking HCQ compared to placebo was determined.
Pediatric Rheumatology 2009, 7:9 http://www.ped-rheum.com/content/7/1/9

Page 7 of 9
(page number not for citation purposes)

...to HCQ. In general the doses used for malarial prophylaxis are less than those used to treat auto-immune diseases. There is a large meta-analysis published by the Cochrane database that included 12,638 patients focused on malaria prevention [32]. No increase in congenital malformations, live births, spontaneous abortions, fetal deaths or pre-maturity was noted in patients who used CQ compared to controls. Although these studies do not directly prove that CQ is safe for pregnant women with auto-immune diseases, it is further evidence of the safety of anti-malarial drugs during pregnancy.

Two of the included studies by Clowse et al. [27] and Frassi et al [30] had an increase in fetal death (OR 4.79 95% CI 0.78, 29.57 and OR 5.40 95% CI 0.26,114.28) in the placebo while another study by Costedoat-Chalumeau et al [28] had an OR of 0.08 (95% CI 0.01, 0.60) that favored HCQ. One possible explanation for this discrepancy is the increased number of patients with anti-cardiolipin antibodies in the HCQ group of Clowse et al [27] and Frassi et al [30] that may have contributed to the high incidence of fetal deaths seen in both studies.

Since anti-malarials cross the placenta, they have the potential to cause congenital defects [12]. The first reports documenting congenital abnormalities and accumulation of the drug in the eye were described in infants whose mothers received chloroquine (CQ) [9,33]. However, recent reports including a Cochrane meta-analysis have demonstrated that CQ in low doses is safe as malaria prophylaxis during pregnancy [34]. In addition to the 4 studies that we included in this report, there have been several uncontrolled studies that have examined the effect of HCQ therapy on ocular toxicity in babies born to

Figure 4
OR of prematurity. The pooled estimate of prematurity for patients taking HCQ compared to placebo was determined.
women taking the drug during pregnancy [35-37]. Two of these studies performed comprehensive ophthalmologic examinations of infants whose mothers took HCQ during pregnancy and found no evidence of ocular toxicity [29,31]. All of these studies have documented the safety of HCQ in infants whose mothers took the medication during pregnancy. The total number of infants examined in these 3 studies is 96.

Another benefit of HCQ during pregnancy is its effect on reducing disease activity. Of note Clowse et al. [27] and Levy et al. [31] made observations of lupus outcomes in a cohort of women with SLE and reported the impact of HCQ treatment cessation on SLE activity during pregnancy. Clowse et al. [27] found that women who stopped taking HCQ had increased lupus activity and increased lupus flares during pregnancy. High activity lupus was defined as a physician’s estimate of activity (PEA) greater than 2 occurred in twice as many pregnancies in which HCQ treatment was stopped as in those in which HCQ was continued. The rate of flare was also higher among women who stopped the medication compared with those who either continued taking it or who never took it. These flares occurred throughout pregnancy. More women who discontinued HCQ treatment had SLEDAI scores greater than 4 during pregnancy and this remained elevated when adjusted for year of delivery, anti-phospholipid antibody syndrome (APS), age, ethnicity, and prior history of lupus nephritis.

The types of lupus activity that were best controlled by HCQ were arthritis and constitutional symptoms. HCQ did not prevent the more severe complications of proteinuria or thrombocytopenia. Furthermore, the authors also evaluated the use of Prednisone and fewer women who continued HCQ required high-dose corticosteroids, defined as either a daily dose of Prednisone of at least 20 mg or pulse steroids. Similar to the observation of Clowse et al. [27], Levy et al. [31] noted that after delivery Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores of the placebo group were not significantly different from pre-treatment scores while in the HCQ group a statistically significant improvement in the score was found; in the HCQ group there were no flares, and there was a statistically significant improvement in the SLEDAI score at delivery when compared to the placebo group.

Conclusion
In conclusion, based on the findings of this meta-analysis, HCQ is not associated with any increased risk of congenital defect, spontaneous abortion, fetal death, pre-maturity or decreased numbers of live births in pregnant patients with auto-immune diseases. Our data demonstrate that HCQ is safe for use during pregnancy.

Competing interests
None of the authors have a financial interest in Sanofi-Winthrop Pharmaceuticals or any other laboratory that manufactures HCQ.

Authors’ contributions
KS did the literature search, the statistical analysis, and wrote the paper. CH and CPC did the blinded grading and quality assessments of the studies. JA and DS wrote the manuscript.

Additional material

References
1. Rymes R: Antimalarial drugs in the treatment of rheumatic diseases. Br J Rheumatol 1997, 36:799-805.
2. Mellman I, Fuchs R, Helerius A: Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 1986, 55:663-700.
3. Oda K, Kariyama Y, Yomada E, Ikahara Y: Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in rat hepatocytes. Biochem J 1986, 240:739-745.
4. Kyburg D, Bretano F, Gay S: Mode of action of Hydroxychloroquine in RA-evidence of an inhibiting effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006, 1:458-459.
5. Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, the LUMINA study group, et al.: Systemic lupus erythematosus in three ethnic groups. XVII. Association of Hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005, 52:1473-1480.
6. Emery P, Suarez-Almazor M: Rheumatoid arthritis. Clin Evid 2003, 9:1349-1371.
7. Vroom F, de Walle HE, Laar MA van de, Brouwers JR, Berg LT de Jong-van den: Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Saf 2006, 29:845-63.
8. Temprano KK, Bandlamudi R, Moore T: Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2003, 32:112-21.
9. Hart CW, Naunton RF: The ototoxicity of chloroquine phosphate. Arch Otalaryngol 1974, 80:407-412.
10. Santalla RM, Fraunfelder FW: Ocular adverse effects associated with systemic medications: recognition and management. Drugs 2007, 67:75-93.
11. Stafford-Brady FJ, Urowitz MB, Gladman DD, Esterbrook M: Lupus retinopathy: patterns, associations, and prognosis. Arthritis Rheum 1988, 31:1105-1110.
12. Costedoat-Chalumeau N, Amoura Z, Aymard G, Le TH, Wechsler B, Vauthier D, Dermer ME, Darbois Y, Piette JC: Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002, 46:123-4.
13. Ostensen M, Khamsia M, Lockshin M, Parke A, et al.: Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Research and Therapy 2006, 8:1-19.
14. Costedoat-Chalumeau N, Amoura Z, Huang DL, Lechat P, Piette JC: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 2005, 4:111-5.
15. Borden MB, Parke AL: Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf 2001, 24:1055-63.
16. Khamashta MA, Buchanan NM, Hughes GR: The use of hydroxychloroquine in lupus pregnancy: the British experience. Lupus 1996, 5(Suppl 1):S56-6.
17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2068-12.
18. Egger M, Smith GD, Altman DG, eds: Systematic reviews in health care: meta-analysis in context 2nd edition. BMJ Books: London, 2002.
19. Downs SH, Black N: The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions. J Epidemiol Community Health 1998, 52:37-41.
20. Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TF, Fiellin DA: Systematic Review: Opioid Treatments for Chronic Back Pain: Prevalence, Efficacy, and Association with Addiction. Ann Intern Med 2007, 146(116-127.
21. Review Manager (RevMan) [computer program]. In Version 4.2 for Windows Copenhagen: The Nordic Centre; 2003.
22. Gert Simonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
23. Harbord RM, Egger M, Sterne JA: A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006, 25:3443-57.
24. Deeks JJ, Altman DG, Bruburn M: Statistical methods for examining heterogeneity and combining results from several studies in a meta-analysis. In Systematic Reviews and Healthcare: meta-analysis in context Edited by: Egger M, Davey Smith G, Altman DG. London BMJ Publications; 2002.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analysis. BMJ 2003, 327:557-560.
26. Hulley SB, Cummings SR, Browner WS, Grady D, Heasrd N, Newman TB: Designing clinical research 2nd edition. Philadelphia: Lippincott Williams and Wilkins; 2001.55-5.
27. Closse ME, Magder L, Winter F, Petri M: Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006, 54:3640-3647.
28. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huang DL, Sebough D, Wechsler B, Vauthier D, Denjojy I, Lupoglazoff JM, Piette JC: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003, 48:3207-11.
29. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR: Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996, 55:486-468.
30. Frassi M, Biasini C, Taglienti M, Daneli E, et al.: Hydroxychloroquine in pregnant patients with rheumatic disease: a case control observation of 76 treated pregnancies. Lupus 2004, 13:755-758.
31. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G: Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991, 1:8174-178.
32. Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, Frassi M, Biasini C, Zatti S, Chirico G: Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005, 25:86-9.
33. Motta M, Tincani A, Faden D, Zinzini E, Chirico G: Antimalarial agents in pregnancy. Lancet 2002, 359:524-5.
34. Parke A, West B: Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996, 23:1715-8.
35. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G: Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991, 8:174-178.
36. Suohon: Hydroxychloroquine administration in pregnancy. Arch Dermatol 1983, 119:185-6.
37. Mintz G, Niz J, Gutierrez G, Garcia Alonso A, Karchmer S: Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach. J Rheumatol 1986, 13:732-739.
38. Lockshin MD: Lupus pregnancy. Clin Rheum Dis 1985, 11:61-163.
39. Lockshin MD, Reinitz E, Druzeal M, Murrman M, Este D: Lupus pregnancy case-control prospective study demonstrate absence of lupus exacerbation during or after pregnancy. Am J Med 1984, 77:393-888.
40. Petri M, Albrightton J: Fetal outcome of lupus pregnancy: A retrospective case-controlled study of the Hopkins lupus cohort. J Rheumatol 1993, 20:650-666.
41. Nossent HC, Swack TJG: Systemic lupus erythematosus. VI: Analysis of the interrelationship with pregnancy. J Rheumatol 1988, 15:771-776.
42. Van Waerren C, Mahon JL, Maerder B, Bohn C, Loupec A: Surveying physicians to determine the minimal important difference: implications for sample size calculations. J Clin Epidemiol 1999, 52:717-723.